Collegium Pharmaceutical Community

Key Takeaways Strategic investments in Journee and extended exclusivity for Nucynta are expected to boost Collegium's revenue through increased awareness and diversified revenue streams. Disciplined capital deployment and strong cash flows support portfolio expansion, debt reduction, and share repurchases, enhancing shareholder value and growth potential.